Early Detection Research Network


This biomarker is also known as:
  • TGB,
  • connective tissue-activating peptide III,
  • TC1,
  • PBP,
  • CXCL7,
  • TC2,
  • Beta-TG,
  • platelet basic protein,
  • leukocyte-derived growth factor,
  • small inducible cytokine B7,
  • macrophage-derived growth factor,
  • LA-PF4,
  • PPBP,
  • pro-platelet basic protein,
  • small inducible cytokine subfamily B, member 7,
  • neutrophil-activating peptide-2,
  • neutrophil-activating peptide 2,
  • low-affinity platelet factor IV,
  • NAP-2-L1,
  • THBGB,
  • CTAP3,
  • NAP-2,
  • thrombocidin 1,
  • MDGF,
  • pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
  • beta-thromboglobulin,
  • CXC chemokine ligand 7,
  • B-TG1,
  • b-TG1,
  • TGB1,
  • LDGF,
  • THBGB1,
  • thromboglobulin, beta-1,
  • thrombocidin 2,
  • SCYB7,


CTAP-III (officially named PPBP) is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and sythesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Three
QA State: Curated


CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis. In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers (apolipoprotein A1 (APOA1), truncated transthyretin (TTR), transferrin (TF), hepcidin (HAMP), β-2 microglobulin B2M), connective tissue activating protein III (CTAPIII, a.k.a PPBP) to CA 125 did not improve sensitivity for preclinical diagnosis of ovarian cancer beyond CA 125 alone.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CTAP-III, also known as PPBP, alone was not a strong predictor.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.